TransMedics Group, Inc. (NASDAQ:TMDX) Given Average Rating of “Hold” by Analysts

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have been given a consensus recommendation of “Hold” by the thirteen research firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have given a hold recommendation and six have given a buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $124.1818.

A number of equities analysts recently commented on the company. UBS Group decreased their target price on TransMedics Group from $80.00 to $77.00 and set a “neutral” rating for the company in a report on Wednesday, August 5th. Oppenheimer downgraded shares of TransMedics Group from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 6th. Zacks Research downgraded shares of TransMedics Group from a “hold” rating to a “strong sell” rating in a research report on Monday, July 6th. Needham & Company LLC decreased their price objective on shares of TransMedics Group from $142.00 to $106.00 and set a “buy” rating for the company in a report on Monday, August 3rd. Finally, Wall Street Zen cut shares of TransMedics Group from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th.

TransMedics Group Trading Up 4.3%

TMDX opened at $94.77 on Friday. The business has a 50 day simple moving average of $77.49 and a two-hundred day simple moving average of $95.32. The firm has a market capitalization of $3.28 billion, a price-to-earnings ratio of 24.36 and a beta of 1.90. The company has a debt-to-equity ratio of 1.62, a current ratio of 6.62 and a quick ratio of 6.07. TransMedics Group has a one year low of $60.10 and a one year high of $156.00.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $0.44 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.06). The business had revenue of $189.95 million during the quarter, compared to the consensus estimate of $184.00 million. TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.TransMedics Group’s quarterly revenue was up 20.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.92 earnings per share. Analysts predict that TransMedics Group will post 1.47 EPS for the current year.

Insider Transactions at TransMedics Group

In related news, Director Thomas J. Gunderson sold 9,624 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $75.06, for a total value of $722,377.44. Following the completion of the transaction, the director directly owned 16,642 shares of the company’s stock, valued at $1,249,148.52. This represents a 36.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is currently owned by insiders.

Institutional Trading of TransMedics Group

Large investors have recently bought and sold shares of the company. FirstWave Capital Management LLC grew its holdings in shares of TransMedics Group by 53.9% during the 2nd quarter. FirstWave Capital Management LLC now owns 191,240 shares of the company’s stock worth $12,702,000 after acquiring an additional 66,972 shares during the period. Plan A Wealth LLC lifted its stake in shares of TransMedics Group by 33.9% in the 2nd quarter. Plan A Wealth LLC now owns 5,167 shares of the company’s stock valued at $343,000 after purchasing an additional 1,308 shares during the period. Braidwell LP lifted its stake in shares of TransMedics Group by 85.1% in the 2nd quarter. Braidwell LP now owns 609,715 shares of the company’s stock valued at $40,497,000 after purchasing an additional 280,324 shares during the period. Headlands Technologies LLC bought a new stake in shares of TransMedics Group during the second quarter valued at approximately $1,634,000. Finally, Flputnam Investment Management Co. bought a new stake in shares of TransMedics Group during the second quarter valued at approximately $77,000. 99.67% of the stock is owned by institutional investors.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.